Recombinant SARS-CoV-2 S protein (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V), His Tag (MALS verified), 50µg

Background
It's been reported that Coronavirus  can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 S protein, His Tag (SPN-C52Hc) is the ectodomain of SARS-CoV-2 S protein that contains AA Val 16 - Pro 1213 (Accession # QHD43416.1) and L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V mutations, which have become increasingly common in SARS-CoV-2 viruses from around the world. The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. L18F/ D80A/ D215G/ R246I/ K417N/ E484K/ N501Y/ D614G/ A701V mutations were identified in the SARS-CoV-2 variant (known as 20B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) which emerged in the United Kindom and SARS-CoV-2 variant (known as 20C/501Y.V2 or B.1.351 lineage) which emerged in South Africa.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.The protein has a calculated MW of 138.0 kDa. The protein migrates as 170-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
Avoid repeated freeze-thaw cycles.
-20°C to -70°C for 12 months in lyophilized state; -70^°C for 3 months under sterile conditions after reconstitution

References

• "Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies" Kumar Verma, Kumar, Singh et al. Biomed Pharmacother (2021) 137, 111356

• "The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor" Hu, Meng, Zhang et al. Emerg Microbes Infect (2021)

• "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment" Munavalli, Guthridge, Knutsen-Larson et al. Arch Dermatol Res (2021)